Dec. 12 at 6:33 PM
Phase 1 of long acting GIPR agonist from
$LLY in non obese diabetics .. clear efficacy of appetite suppression , wt loss at 35 days ( that lasted till day 57. Last shot day 35, Average baseline wt 74 Kg )
Only side effect appetite suppression. No single case of nausea or vomiting
Clarify the role of GIP in synergy with GLP1 for wt loss and also mitigating nausea
$NVO had its trial presented recently that didn’t show added wt loss of their GIP1 agonist when added to semaglutide ( I don’t have data ). Again novo team should review internal peptides and lipid chains and compare to what others doing.
Paper in support of
$LLY and
$VKTX focus on GLP1 GIP and argues against
$AMGN approach.
https://www.sciencedirect.com/science/article/pii/S2212877825002054
